Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05)

BACKGROUND: Therapy of primary CNS lymphoma (PCNSL) has focused on multi-agent chemotherapy designed to cross the blood brain barrier. Rituximab has demonstrated activity in PCNSL. E1F05 is an ECOG-ACRIN multicenter phase 2 prospective trial of rituximab with high-dose methotrexate (HD-MTX)-based ch...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Swinnen, Lode J., O’Neill, Anne, Imus, Philip H., Gujar, Sachin, Schiff, David, Kleinberg, Lawrence R., Advani, Ranjana H., Dunbar, Erin M., Moore, Dennis, Grossman, Stuart A.
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5787508/
https://ncbi.nlm.nih.gov/pubmed/29416652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22332
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados